Answers are grounded in this paper and cite their sources.
Membranous glomerulonephritis (MGN) is the commonest cause of the nephrotic syndrome in adults.1,2 The majority of cases are idiopathic (primary MGN), however ∼30% are secondary to systemic diseases such as SLE, epithelial malignancies, medications or exposure to heavy metals.3 Recently, an autoantibody has been identified in >70% of cases of idiopathic MGN with specificity for the M-type phospholipase A2 receptor (PLA2R).4 Skin-lightening creams, which may contain mercury salts, are widely used in ethnic subgroups where paler skin is seen as a desirable attribute.5 With prolonged use, mercury toxicity can occur, leading to the development of autoimmune phenomena and renal dysfunction.6 We describe two cases of biopsy-proven MGN associated with elevated serum and urine mercury levels in females who used skin-lightening creams containing mercury that had been manufactured in the UK. Neither patient had antibodies against the PLA2R providing further evidence for the specificity of this antibody for primary MGN. A 44-year-old woman originally from Pakistan was referred for investigation of the nephrotic syndrome. She had peripheral oedema, an albumin of 32 g/l, a plasma creatinine of 95 µmol/l (eGFR59 ml/min/1.73 m2) and a urine protein–creatinine ratio of 1419 mg/mmol (normal <30). Her history included peptic ulcer disease and vitamin D deficiency, which had been diagnosed 4 months before the current presentation (total vitamin D 2.8 ng/ml, where <6 ng/ml represents severe deficiency). Her regular medications were omeprazole and alfacalcidol. She denied taking any other medications, over the counter preparations or herbal remedies. Investigations for secondary causes of a nephrotic syndrome, including HBV and HCV serology and an autoimmune screen were all negative. A renal biopsy was performed, which showed MGN. Because of the patient’s ethnic background, low vitamin D levels and previous case reports describing MGN in association with skin-lightening creams,7,8 serum and urine mercury levels were measured and found to be elevated (serum mercury 150 nmol/l (normal <30), urine mercury 16.5 nnmol/mmol (normal <5.5). The patient then admitted to using a skin-lightening cream on her face, which had been purchased from a local shopping channel. Her general practitioner arranged for measurement of the mercury content of the cream, which was found to be 2% mercury w/w. After stopping use of the cream, her blood and urine mercury levels slowly declined, as did her proteinuria. Unfortunately her renal function worsened and remains impaired with a current creatinine of 136 µmol/l (eGFR = 38 ml/min/1.73 m2). A 26-year-old Pakistani woman was referred by her general practitioner with heavy proteinuria, detected in the course of investigations for peripheral and periorbital oedema. Laboratory results confirmed the nephrotic syndrome, albumin 28 g/l, proteinuria of >9g/day, with normal renal function (creatinine 62 µmol/l eGFR >90 ml/min/1.73 m2). She was on no regular medication and denied taking any herbal or over the counter preparations, including NSAIDs. Screening investigations failed to identify a cause for the nephrotic syndrome and she underwent a renal biopsy, which revealed MGN. As her face was noted to be much lighter in colour than her hands (Figure 1) and our previous diagnosis of a case of mercury-induced MGN, she was specifically asked whether she used a skin-lightening cream and confirmed that she did. Serum and urine mercury levels were requested and were elevated; blood mercury 233 nmol/l (normal <30), urinary mercury-creatinine ratio 77.5 nmol/mmol (normal <5.5). After ceasing application of the cream, her nephrotic syndrome resolved (albumin 38 g/l), however her proteinuria persists (urinary protein: creatinine ratio 238 mg/mmol). Her renal function has remained normal throughout. Photograph of Case 2. The difference in skin colour between her face and hand is shown. MGN is associated with significant morbidity and mortality, with 20–50% of patients developing progressive renal impairment.9,10 Histologically, the defining feature of MGN is the appearance of prominent basement membranes in the glomeruli on light microscopy, usually associated with characteristic membrane spikes best seen in silver-stained sections (Figure 2). Immunostaining shows deposits of IgG and C3, which appear as dense deposits with electron microscopy. In idiopathic MGN, the immunoglobulins are usually of the IgG4 subclass, whereas in secondary MGN, other IgG subclasses and non-IgG immunoglobulins usually predominate.11 In patients with secondary membranous, histological and clinical changes may resolve after treatment of the underlying condition or withdrawal of the offending agent.8,12 Renal biopsy from Case 1. The H&E stain (A) shows diffuse thickening of the capillary walls with otherwise normal appearing glomeruli. The silver stain (B) highlights the membrane spikes. The IgG subtype staining (C) deposits of IgG1 (D) deposits of IgG2 (E) deposits of IgG3 and (F) deposits of IgG4. The IgG4 predominance is more common in idiopathic MGN. In animal models, chronic mercury exposure leads to the development of proteinuria associated with the presence of circulating autoantibodies directed against glomerular and non-glomerular antigens.13–15 Whether mercury-induced immune stimulation could trigger the formation of antibodies against the recently described PLA2R, as occurs in idiopathic membranous GN was unknown. Serum samples from our patients were tested and found to be negative (Figure 3). Western blot for antibodies against the PLA2R. Neither case had evidence of antibodies against the phospholipase A2 receptor (rPLA2R) or any intrinsic glomerular antigen, as shown by the absence of bands in the HGE (human glomerular extract) lanes. A patient with idiopathic MGN (IMGN) is shown as a positive control. Skin-lightening agents are used therapeutically to treat hyperpigmentation,16 however there is now a large (and growing industry) promoting the use of these products for people who wish to appear paler. Some of these creams have been demonstrated to contain significant amounts of mercury,17,18 which over time can lead to systemic toxicity, with the development of peripheral neuropathy, dermatitis, renal impairment and autoimmune phenomena. As there are large numbers of immigrants to the UK from countries where use of these creams is widespread, doctors should be aware of this ‘imported’ condition, as our cases are likely to be representative of a more widespread problem. Given the social and cultural prejudices related to appearance, it is perhaps not surprising that neither patient disclosed using skin-lightening creams until directly questioned. Clinicians should be alert to the possibility of mercury toxicity in patients presenting with new-onset proteinuria and specifically question them on the use of products that may contain mercury. In patients with mercury-induced MGN, antibodies to the M-Type PLA2R do not appear to be present, further supporting the use of this antibody for diagnosis of the idiopathic form of the disease. Conflict of interest: None declared.
No takes yet. Share an insight, caveat, or question.
Chakera et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: